TRANSCAN-3 JOINT TRANSNATIONAL CALL 2022
"Novel translational approaches to tackle the challenges of hard-to-treat cancers from early diagnosis to therapy"
is open for submission
Please visit the TRANSCAN-3 website at
Other news (outside TRANSCAN):
The Digital Institute for Cancer Outcomes Research (DIGICORE), a 30-strong network of cancer centres established as an EU European Economic Interest Group, is delighted to announce an innovative new training programme for early career researchers in oncology.
IDEAL4RWE is a new training program to equip early-career researchers (<45 years old) with the technical and leadership skills to build collaborative teams for oncology RWE research.
Please register for an introductory webinar on the 19th April 2022 (https://lnkd.in/ez7y4kWU).
Brochure for more details: https://tinyurl.com/y7aurdtk
International Networking Event (virtual)
was held on 22 April 2021 hrs 9:00 CET
focussed on the co-funded Joint Transnational Call for proposals, JTC2021, on:
"Next generation cancer immunotherapy: targeting the tumour microenvironment"
event organized by TUBITAK under the “Turkey in Horizon 2020 Phase II” Technical Assistance Project
in cooperation with TRANSCAN-3
The 3rd and final TRANSCAN-2 symposium on Tumour Heterogeneity was held in Milan on October 24th, 2019
The symposium included talks from the funded consortia of JTC2014 co-funded by the EU, an exciting discussion on the impact and added value of transnational collaborations on cancer research and a poster prize competition for young scientists.
The event was hosted by Regione Lombardia, Italy, with the collaboration of Fondazione Regionale per la Ricerca Biomedica
JTC 2017 on: Translational research on rare cancers
12 projects selected for funding, visit the page
JTC 2016 on: Minimally and non-invasive methods for early detection and/or progression of cancer.
JTC 2015 on: Immunology and immunotherapy of cancer: strengthening the translational aspects.
JTC 2014 on: Translational research on human tumour heterogeneity to overcome recurrence and resistance to therapy.